Inventor · disambiguated record
Rajesh Gandhi
Also filed as: GANDHI RAJESH · GANDHI RAJESH B · GANDHI RAJESH BABULAL
13 granted patents·17 pending applications·85 citations·filing 1995–2024
91Inventor score
Files withBRISTOL MYERS SQUIBB CO6GANDHI RAJESH4Dr Reddys Laboratories Ltd3RAHEJA PRAVEEN3RANBAXY LAB LTD3
Top patents by PatentIndex Score
30 records- 0191US12090139B2Formulations comprising triptan compoundsTONIX MEDICINES INC·Filed 2022·Granted Sep 17, 2024·3 cites·13 claims
- 0291US9309316B2Stable subcutaneous protein formulations and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2013·Granted Apr 12, 2016·14 cites·44 claims
- 0390US8476239B2Stable protein formulationsDALI MANISHA M·Filed 2006·Granted Jul 2, 2013·40 cites·15 claims
- 0489US10603305B2Formulations comprising triptan compoundsUPSHER SMITH LABORATORIES LLC·Filed 2018·Granted Mar 31, 2020·3 cites·21 claims
- 0586US11337962B2Formulations comprising triptan compoundsUPSHER SMITH LABORATORIES LLC·Filed 2020·Granted May 24, 2022·2 cites·11 claims
- 0683US9974770B2Formulations comprising triptan compoundsDr Reddys Laboratories Ltd·Filed 2017·Granted May 22, 2018·3 cites·20 claims
- 0783US2025195470A1Formulations comprising triptan compoundsTONIX MEDICINES INC·Filed 2024·Application pending·0 cites
- 0882US9610280B2Formulations comprising triptan compoundsDr Reddys Laboratories Ltd·Filed 2015·Granted Apr 4, 2017·3 cites·16 claims
- 0980US8911787B2Stable oral benzimidazole compositions and process of preparation thereofRANBAXY LAB LTD·Filed 2014·Granted Dec 16, 2014·4 cites·16 claims
- 1077US2023277672A1METHODS OF USING CTLA4Ig SUBCUTANEOUS FORMULATIONSBRISTOL MYERS SQUIBB CO·Filed 2022·Application pending·0 cites
- 1175US9211282B2Formulations comprising triptan compoundsGANDHI RAJESH·Filed 2010·Granted Dec 15, 2015·3 cites·21 claims
- 1273US10265401B2Stable subcutaneous protein formulations and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2016·Granted Apr 23, 2019·1 cites·16 claims
- 1367US2018360965A1Stable subcutaneous protein formulations and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2018·Application pending·0 cites
- 1466US2020230242A1METHODS OF USING CTLA4Ig SUBCUTANEOUS FORMULATIONSBRISTOL MYERS SQUIBB CO·Filed 2020·Application pending·0 cites
- 1560US2009130210A1Pharmaceutical compositions of sirolimusRAHEJA PRAVEEN·Filed 2008·Application pending·0 cites
- 1653US2010144800A1extended release tablet formulation of niacinRANBAXY LAB LTD·Filed 2009·Application pending·0 cites
- 1752US2016000799A1Pharmaceutical compositions of cetp inhibitorsREDDYS LAB LTD DR·Filed 2014·Application pending·0 cites
- 1852US2009068266A1Sirolimus having specific particle size and pharmaceutical compositions thereofRAHEJA PRAVEEN·Filed 2008·Application pending·0 cites
- 1950US5608048Ad4 T polymorphic Form 1 processBRISTOL MYERS SQUIBB CO·Filed 1995·Granted Mar 4, 1997·9 cites·5 claims
- 2047US2008138405A1Sirolimus nanodispersionRAHEJA PRAVEEN·Filed 2007·Application pending·0 cites
- 2147US2008279951A1Stable Oral Benzimidazole Compositions Prepared by Non-Aqueous Layering ProcessGANDHI RAJESH·Filed 2006·Application pending·0 cites
- 2245US8658216B2Stable oral benzimidazole compositions and process of preparation thereofGANDHI RAJESH·Filed 2005·Granted Feb 25, 2014·0 cites·15 claims
- 2345US2006159758A1Coating composition for taste masking coating and methods for their application and useGANDHI RAJESH·Filed 2003·Application pending·0 cites
- 2445US2009220598A1Stable Oral Pharmaceutical Composition Containing Thyroid Hormone Receptor AgonistsGARG NEERAJ·Filed 2007·Application pending·0 cites
- 2543US2010178341A1BILAYERED TABLET COMPRISING NIACIN AND HMG-CoA REDUCTASE INHIBITORRANBAXY LAB LTD·Filed 2009·Application pending·0 cites
- 2643US2017071930A1Pharmaceutical compositions of cetp inhibitorsDr Reddys Laboratories Ltd·Filed 2013·Application pending·0 cites
- 2743US2013259947A1Oral metronidazole pharmaceutical compositionsPADHI BIJAY KUMAR·Filed 2011·Application pending·0 cites
- 2840US2006128726A1Process for preparing novel crystalline forms of (2S)-1-[[(7R)-7-(3,4-dichlorophenyl)-4,7-dihydro-5-methylpyrazolo[1,5]pyrimidine-6-yl]carbonyl]-2-(4-fluorophenyl)pyrrolidine, novel stable forms produced therein and formulationsWANG XUEBAO·Filed 2005·Application pending·0 cites
- 2934US2003225279A1Stavudine Polymorphic Form 1 processFiled 2002·Application pending·0 cites
- 3029US8252821B2Bioavailable capsule compositions of amorphous alpha-(N-sulfonamido)acetamide compoundCHANDRAN SACHIN·Filed 2010·Granted Aug 28, 2012·0 cites·30 claims
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →